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HAART has significantly changed the natural history of HIV infection: patients receiving antiretrovirals are usually able to control
viremia, even though not all virological responders adequately recover their CD4+ count. The reasons for poor immune restoration
are only partially known and they include genetic, demographic and immunologic factors. A crucial element aﬀecting immune
recovery is immune activation, related to residual viremia; indeed, a suboptimal virological control (i.e., low levels of plasma HIV
RNA) has been related with higher levels of chronic inflammation and all-cause mortality. The sources of residual viremia are not
yet completely known, even though the most important one is represented by latently infected cells. Several methods, including 2-
LTR HIV DNA and unspliced HIV RNA measurement, have been developed to estimate residual viremia and predict the outcome
of antiretroviral therapy. Considering that poor immunologic responders are exposed to a higher risk of both AIDS-related and
non-AIDS-related diseases, there is a need of new therapeutic strategies, including immunomodulators and drugs targeting the
latent viral reservoirs, in order to face residual viremia but also to “drive” the host immunologic responses.
1. Introduction
The introduction of highly active antiretroviral therapy
(HAART) has determined a significant reduction in mor-
bidity and mortality of people living with human immun-
odeficiency virus (HIV) [1]. The majority of individuals
taking HAART experience HIV RNA suppression below
the detection limit of clinical assays (usually 20–50 copies
HIV RNA/mL plasma) [2, 3]. However, despite suppressing
viremia, HAART cannot eradicate HIV: residual low level
viremia (LLV) can indeed be detected in most patients
with ultrasensitive assays, because of the persistency of
viral reservoirs and “sanctuary sites” not fully aﬀected by
HAART [4–7]. In addition to plasma HIV RNA, several
protocols have been developed to estimate the burden of viral
replication, including 2 “long terminal repeat” (LTR) HIV
DNAs, a marker of recent cellular infection, and multispliced
(MS) and unspliced (US) HIV RNA quantification [8]. Of
note, not all virologically suppressed patients are able to
recover their CD4+ T-cell count, thus representing a great
concern because of the risk for opportunistic infections.
The reasons for defective immune restoration are not
fully understood: reduced CD4+ T-cell recovery has been
associated with older age [9–14], higher HIV RNA before
HAART [10, 12, 15–19], lower baseline CD4+ count [10–12,
20–22], bone marrow [23, 24], and thymic dysfunction [25–
27]; genetic factors, including CCR5 polymorphism [28],
some antiretroviral drugs [29–31], and immune activation
[32] has also been related with impaired immune restoration.
In this paper, we first describe the mechanisms which
may aﬀect immune restoration, focusing on the role of
immune activation and residual viremia. We briefly outline
the main sources of LLV and the most commonly used
assays to identify latently infected cells and we report
the most recent evidence about the clinical implications
related to LLV. We then summarize the potentialities of
new therapeutic options, including immune therapy and
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“reactivation strategies,” in reconstituting immune functions
of HIV-infected subjects.
2. Definition and Timing of Immune
Restoration
The increase in peripheral CD4+ T cells observed during
HAART occurs in three distinct phases: during the first
3–6 months of HAART, the significant increase (20–30
cells/μL monthly) in circulating naive and memory CD4+
T cells may be explained by the redistribution of T cells
from the lymphoid tissues to the blood [33–35]; viral
load suppression, with the subsequent decrease in immune
activation, has been shown to downregulate the expression
of adhesion molecules on the surface of T cells, such as
intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1), which are responsible
for T-cell trapping in the lymphoid organs. This mechanism
results in T-cell dismissal in the blood [36]. The second phase
(5–10 cells/μL monthly, until the end of the second year of
HAART) and the third phase (2–5 cells/μL monthly, until at
least the seventh year of antiretroviral therapy) of immune
restoration are due to several mechanisms, globally leading
to the rise in T cells, especially naive ones [10, 37, 38]: the
stimulation of thymic lymphopoiesis and the proliferation
of residual CD4+ T cells are the main causes of immune
restoration [39]; lifespan increase of CD4+ T cells may also
account for T-cell recovery under HAART, especially in older
subjects, who physiologically have a reduced thymic function
[40]. Of note, these potentially compensatory responses
to HIV infection do not have the same immunological
meaning, considering that de novo proliferation of CD4+ T
cells may potentially restore a complete T-cell repertoire; by
contrast, the increased proliferation and survival of residual
CD4+ T cells, even if able to apparently guarantee T-cell
recovery, is not associated with a good quality of immune
reconstitution, because of its inability to reconstitute a
complete T-cell repertoire.
In most studies, a strong correlation between the magni-
tude of the change in plasma HIV RNA and the increase in
circulating CD4+ T cells has been described. Le Moing et al.
[37] reported a significant association between the long-term
slope of CD4+ T cells and the variation of plasma HIV RNA
levels when studying a large cohort of HIV-infected patients
at the initiation of a protease-inhibitor- (PI-) containing
antiretroviral regimen. In fact, the long-term slope was
2.5 cells/mm3/month higher in patients who had plasma
HIV RNA levels of less than 500 copies/mL at month 4
(P < 0.001), in comparison with those having no virological
response. Nevertheless, this increase in CD4+ T-cell count
was significantly attenuated after occurrence of a rebound
in plasma HIV RNA > 500 copies/mL, thus suggesting
the importance to achieve and maintain a good virological
control. PretreatmentHIVRNA levels have been significantly
correlated with CD4+ T-cell recovery in several studies [14,
37–39]: as previously noticed, this observation may be due
to the fact that higher plasma HIV RNA levels associate with
greater numbers of CD4+ T cells being sequestered within
lymphatic tissues, resulting in a greater redistribution of cells
after HAART-induced viral suppression.
It is interesting to note that CD4+ T-cell recovery
under HAART does not lead to the full restoration of
humoral and cellular immune functions. Indeed, a number
of studies have described functional impairment of both
innate and acquired immune responses despite eﬀective
HAART. Chehimi et al., for instance, observed only a partial
recovery of functional plasmacytoid dendritic cells (PDCs)
and natural killer (NK) cells after 52 weeks of suppressive
HAART [41]. In this study, patients were divided into two
groups, one composed of subjects achieving rapid viral
load suppression (HIV RNA < 50 copies/mL by week
12), the other composed of subjects with delayed viral
suppression. Subjects with delayed viral suppression had
a higher baseline viremia (29.254 copies/mL versus 4.134
copies/mL); moreover, baseline viral load was a negative
predictor of PDCs recovery after 52 week of HAART (r =
−0.47, P = 0.08). Restoration of total NK cells was incom-
plete even after 52 weeks on HAART when considering the
whole HIV-positive cohort (73 cells/μL versus 122 cells/μL
in controls). Furthermore, cytokine-induced IFN-gamma
production by NK cells has been shown to be similarly
impaired in asymptomatic, viremic, and HAART-suppressed
HIV-positive subjects [42]. Stone et al. [43] found that CD4+
T cells from HIV-infected patients had increased expression
of the coinhibitory protein cytotoxic T-lymphocyte antigen-
4 (CTLA-4) and decreased expression of the costimulatory
protein CD28, even in presence of increased CD4+ T-cell
count and great control of HIV viral load by HAART. CTLA-
4 and CD28 play a crucial role in T-cell activation after
engagement by CD80/CD86 on antigen-presenting cells, so
that their dysregulated expression on T cells may contribute
to impaired T-cell functions.
There is not a consensus definition of immunologic
nonresponder individuals: some authors described patients
on HAART whose CD4+ T-cell count remained below a
critical threshold, ranging between 350 and 500 cells/μL,
over an extended period of time (more than 4–7 years in
most studies), as poor immune responders, in which viro-
immunologic dissociation implies a greater risk of AIDS-
related and non-AIDS-related illnesses [44–46]; some others
analyzed immune recovery over a shorter period of time,
usually 6–12 months of HAART, defining as immunologic
nonresponders those patients whose CD4+ T-cell count
increase was <30% and total CD4+ T-cell count ≤ 200
cells/μL [47].
3. Risk Factors for Impaired CD4+ T-Cell
Recovery
Immunologic nonresponse despite eﬀective HAART appears
to have a multifactorial origin, since a number of host-
related and HIV-related factors contribute to a suboptimal
immune reconstitution [48] (Figure 1). Some demographic
characteristics, like male sex and older age, have been
associated with reduced CD4+ T-cell gain: these findings
may be explained by the fact that thymic output is higher
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Risk factors for impaired CD4+ T-cell recovery
- Older age and male sex
- Low baseline CD4+
- High baseline HIV RNA
- Thymic and bone marrow dysfunction
- Immune activation (microbial translocation, HCV coinfection, and residual viremia)
- Ongoing HIV replication
- Antiretrovirals (didanosine, AZT)
- CCR5-induced T-cell activation (CCR5 genetic polymorphism)
Factors associated with greater CD4+ T- cell gain
- Younger age and female sex
- Higher nadir CD4+
- Optimal adherence to HAART
- PI-based HAART
Figure 1: Factors aﬀecting immune restoration in patients on HAART.
in women and younger subjects and it is closely associated
with de novo production of CD4+ T cells [49]. In fact,
impaired central regeneration of T cells, consistent with
altered thymopoiesis, has been reported as a key determinant
of poor immune reconstitution. T-cell receptor (TCR)
excision circles (TRECs) have been used as a surrogate
marker of thymic output, because they represent sequences
of extrachromosomal DNA which are not replicated during
T-cell divisions and therefore are not present in the progeny.
In subjects with reduced immune restoration, a lower level
of TRECs in T cells has been found by some authors
[50, 51]; in addition, a lower percentage of recent thymic
immigrant CD4+ T cells (CD31+%), has been described in
immunologic nonresponders in comparison with immuno-
logic responders [52], thus supporting, again, the contribute
of thymic exhaustion to poor CD4+ gain despite suppressive
HAART [25–27]. It remains to be established if it is the
thymus itself to be unable to respond to thymopoietic signals,
for example, IL-7, or if it is the insuﬃcient production of
thymopoietic molecules to compromise thymic-dependent
immune recovery. IL-7 is a potent pleiotropic cytokine
implicated in both thymopoiesis and peripheral homeostasis.
IL-7 is constitutively produced by stromal cells from the bone
marrow and thymus. In the thymus, it supports the viability
and the expansion of early thymocytes; at the peripheral
level, it costimulates T cells, thereby initiating their pro-
liferation and survival. Furthermore, it has been shown to
increase CD8+ T-cell cytotoxicity and to promote NK-cell
functions [53]. IL-7 production is increased in lymphopenic
conditions [54]. In fact, when studying a cohort of 168
HIV-positive patients, Napolitano et al. found higher IL-7
levels to be independently associated with lower CD4+ T-
cell count (P = 0.0001) and higher plasma HIV RNA levels
(P = 0.002). Consistent with the findings of the cross-
sectional study, the longitudinal analysis of a smaller cohort
of 11 HIV-infected patients, observed over 6–25 months,
confirmed the increase in IL-7 levels to be significantly
associated with a decrease in the CD4+ T-cell count (ρ =
−0.64; P = 0.03) but not with changes in viral load anymore
(ρ = −0.41; P = 0.21). Despite similar IL-7 plasma
levels in immunologic responders and nonresponders, it
has been shown that patients with poor immune recovery
are characterized by reduced IL-7 receptor expression on
diﬀerent T-cell populations, thus potentially limiting the
compensatory eﬀect of higher IL-7 levels [55]. Female sex
hormones have been shown to exert an antiapoptotic role
on neutrophils [56]; it may be speculated a similar function
on CD4+ T cells, which may at least partially explain the
greater immune restoration found in women in comparison
with men. A more direct link between T-cell recovery and
gender has been recently described by Olsen and Kovacs,
who demonstrated that the thymus is a target for androgen
hormones, as suggested by the observation of increased
thymic T-cell output in hypogonadal men [57]. The role
of genetics has been emphasized by several authors: the
stimulation of C-C chemokine receptor type 5 (CCR5)
on CD4+ T-cell surface has been associated with T-cell
activation [58]; in subjects carrying a CCR5 polymorphism,
determining CD4+ T-cell activation, the polymorphism has
been found to be predictive of immunologic response [28].
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Multiple studies reported that patients receiving PI-based
regimens had a better T-cell recovery [59–62], possibly
because PIs may restore T-cell proliferative responses [63]
and activate antiapoptotic pathways [64]. The administra-
tion of other antiretroviral drugs has been reported to have a
deleterious eﬀect on CD4+ T-cell gain: AZT, for instance, has
been shown to be toxic for hematopoietic progenitors [29],
didanosine to block T-cell proliferation and diﬀerentiation
[30].
Immune activation is considered a key element in
determining poor immune restoration [23, 32, 55, 65–67]:
the immune system of HIV-infected subjects has to cope
with a massive T-cell apoptosis [68, 69], which appears
closely associated with the continuous stimulatory eﬀect
of proinflammatory cytokines and viral antigens [70]. The
depletion of CD4+ T cells in mucosal lymphoid tissues is
considered a key element of immune activation, because
it leads to the disruption of the mucosal barrier in the
gut, whose physiological function is to prevent microbial
translocation from the gut to the systemic immune system
[70–73]. Microbial translocation results in elevated plasma
levels of bacterial 16s DNA and lipopolysaccharide (LPS)
[73, 74], which have been directly correlated with reduced
CD4+ T-cell recovery after starting HAART [66, 73, 74].
Coinfection with HCV [75–77] or Herpesviridae (EBV,
CMV) reactivation [78, 79] have also been associated with
immune activation and poor CD4+ T-cell recovery.
4. Residual Viremia, HIV Latency, and Poor
Immune Restoration
Residual viremia has been shown to trigger immune activa-
tion [48]: it is not yet well known if residual LLV represents
the result of ongoing cycles of viral replication or if it is
caused by the release of virus from stable HIV reservoirs
[80]. As refers to the first hypothesis, some authors have
recently shown that there is not evolution in HIV genome
during HAART, thus implying the absence of ongoing cycles
of productive viral replication. Furthermore, the character-
ization of rebounding virus during structured therapeutic
interruptions has shown no evidence of evolution when
compared with pretreatment samples [81]; analogously,
some studies reported that HAART intensification with the
addition of raltegravir, in patients on suppressive regimens,
did not significantly decrease viremia, thus suggesting, again,
the absence of ongoing cycles of replicating virus [82–85].
Further support to this observation emerged from earlier
studies, showing that the level of persistent viremia was not
related to treatment regimen but to pretreatment viral load;
all eﬀective HAART regimens suppressed HIV viral load to
the same average level, a level that was not determined by the
regimen itself, but by the size of the viral reservoirs [86]. On
the other hand, some authors have reported opposing results:
the presence of extrachromosomic HIV DNA, including
circular DNA containing “long terminal repeat” sequences
(LTR), a putative marker of recent cell infection, has been
found in virologically suppressed patients [87]; likewise, an
increase in the amount of 2-LTR forms of HIV DNA in
the peripheral blood mononuclear cells (PBMCs) of patients
under treatment intensification with raltegravir supported
the idea of the persistency of ongoing replication [88].
The presence of long-lived latently infected cells is
generally considered the main cause of LLV. HIV latency
occurs in resting central memory (Tcm) and transitional
memory (Ttm) CD4+ cells [89], but also in astrocytes [90,
91], monocyte-macrophages [92], naive T cells [93, 94], and
thymocytes [95]. Latently infected cells can be detected in
blood and tissues, such as the gastrointestinal tract [96], the
central nervous system [91, 97], the genital tract [98–100],
which represent “sanctuary sites”, where HAART poorly
penetrates. When activated, latently infected CD4+ T cells
can release the virus in the blood, even if antiretrovirals are
able to prevent new rounds of infection; during HAART,
these cells decay very slowly, with an average half-life of 44
months, so that under current treatment it will take over 60
years to deplete this reservoir [101]. The pretreatment HIV-1
DNA level in PBMCs has been identified as a relevant marker
in predicting residual viremia for patients receiving an
identical HAART regimen [4], as cell-associated HIV DNA
is considered a good surrogate marker of the total number of
latently infected cells [102]. Quantification of cell-associated
unspliced (US) and multiply spliced (MS) HIV RNA has
been proposed as an helpful tool to estimate residual
productively infected cells and to predict the virological
outcome of therapy in patients on HAART: Pasternak et al.
demonstrated that the level of HIV US RNA in PBMCs,
as measured in HAART-treated patients with undetectable
viremia, strongly correlated with the likelihood to experience
HAART failure. In fact, median US RNA levels were signif-
icantly higher in patients who underwent HAART failure
(0.43 log10 diﬀerence, P = 0.0015) in comparison with
those who remained virologically suppressed and inversely
correlated with baseline CD4+ T-cell count; furthermore, in
multivariate analysis, after adjusting for baseline CD4+ T-
cell count, prior HAART experience and particular HAART
regimens, the maximal US RNA level under therapy was
the best independent predictor of subsequent therapy failure
(adjusted odds ratio [95% CI], 24.4 [1.5–389.5], P = 0.024)
[103].
Several studies have shown that the persistency of
residual viremia represents a continuous proinflammatory
stimulus for the immune system, causing immune activation
and chronic inflammation. Of interest, a recent work of
d’Ettorre et al. [104] has found out the association of HIV
persistence in the gut mucosa of HAART-treated subjects
with immune activation and microbial translocation: in
fact, the level of HIV DNA in the gut correlated with
plasma level of LPS and with the levels of expression
of the activation marker CD38 on CD8+ T cells. In the
SMART trial, levels of C-reactive protein (CRP), Interleukin
(IL)-6, and D-Dimer remained elevated in HIV-infected
subjects, despite suppressive HAART [105]; furthermore, IL-
6 and D-Dimer were strongly associated with mortality, even
in patients achieving viral suppression [106]. Contrasting
results were recently published by Eastburn et al. [107]. The
authors explored the association of LLV with inflammation,
increased coagulation, and all-cause mortality and they
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unexpectedly found little association of LLV with CRP, IL-
6 and fibrinogen: in fact, CRP levels did not correlate with
HIV viral load, while increasing HIV RNA was associated
with higher IL-6 and fibrinogen levels, but only for subjects
whose viral load was above 10.000 copies/mL. As refers to IL-
6, this association was attenuated by ∼50% after adjusting
for CD4+ T-cell count. In addition, HIV RNA was not
associated with mortality risk over 5 years, after adjustment
for CD4+ T-cell count, cardiovascular risk factors, and
inflammation. These contrasting data suggest the need for
more studies, properly designed to identify the most reli-
able coagulopathic/inflammatory markers associated with
HIV ongoing replication/persistence and to further explore
whether LLV predisposes to increased inflammation and all-
cause mortality. Furthermore, in addition to cross-sectional
plasma HIV RNA measures, some authors have investigated
the use of other biomarkers, which may be able to better
describe the patient longitudinal exposure to HIV burden
and to potentially work as a proxy measure of cumulative
inflammation and immune system activation [108, 109].
Mugavero et al. have recently proposed viremia copy-years,
a time-varying measure of cumulative plasma HIV exposure,
as an independent predictor of mortality, even after adjusting
for most recent CD4+ T-cell count, thus substantiating the
role of HIV replication in accelerating disease progression,
independently of its eﬀects on peripheral CD4+ T-cell
depletion [108].
5. Potential Strategies to Reduce Residual
Viremia and Enhance Immune Restoration
Considering that functional and numerical normalization
of CD4+ T-cells appears to be fundamental to prevent
both AIDS-related and non-AIDS-related morbidity and
mortality, there is a need of new therapeutic strategies for
immunologic nonresponder patients (Figure 2).
We have previously highlighted the crucial role of
immune activation in causing poor CD4+ T-cell gain in
patients receiving HAART; therefore, strategies aiming at
reducing immune activation would be worthy to enhance
immune restoration. An attempt to suppress polyclonal
T-cell activation has been made by some authors
using immunosuppressive drugs, such as hydroxyurea,
corticosteroids, cyclosporine A, mycophenolate, with no
eﬀective results, even considering that immunosuppressive
adverse eﬀects may overwhelm the theoretical benefits of
reduced T-cell activation [110]. More encouraging results
have been associated with the use of maraviroc, a CCR5
antagonist, which has been shown to reduce the levels of
activated CD4+ and CD8+ T cells [111, 112] and to induce
a greater increase in CD4+ T-cell count in treatment naive
patients at week 48 and 96, in comparison with efavirenz
[113]. The anti-inflammatory and immunomodulatory
functions of statins have recently been evaluated by De
Wit et al., who have shown atorvastatin to significantly
reduce the level of immune activation, measured by
CD8+/CD38+ percentage, but not to aﬀect highly sensitive
CRP levels or CD4+ T-cell response in HAART-suppressed
Reducing immune activation (e.g., 
CCR5 antagonists, TLR-4 
Boosting immunity (therapeutic
Gene therapy (e.g., RNA-based
gene therapy to reduce CCR5 
expression)
Reducing latently infected cells
prostratin, HDACis, 
methylation inhibitors)
HAART
antagonists, anti-IL-1β, anti-IL-6)
vaccination, rIL-2, IL-7, IL-15)
(e.g., IL-7,
Figure 2: Therapeutic options for increasing CD4+ T-cell recovery.
HAART obviously remains the milestone of any treatment; in addi-
tion, other potential strategies, targeting some aspects associated
with poor immune restoration, are here reported.
patients [114]. As refers to microbial translocation, the
use of probiotics has been suggested to favorably modify
the balance between “good” and “bad” intestinal flora;
furthermore, the use of inhibitors of bacterial product-
mediated eﬀects (antagonists of toll like receptor-4, the
receptor for LPS [115]) or inhibitors of proinflammatory
cytokines (anti-IL-1β, anti-IL-6 or antitumor necrosis
factor (TNF)-α [116]) is another option currently under
evaluation. The antiviral and anti-inflammatory properties
of the antimalarial drug hydroxychloroquine (HCQ) have
recently been analyzed in a cohort of 20 HAART-treated
immunologic nonresponders by Piconi et al. [117], who
studied the impact of HCQ (400mg/day for 6 months) on
immune activation: HCQ significantly reduced plasma LPS,
LPS/TLR-mediated signal transduction and IL-6/TNF-α
production; furthermore, it increased percentages of cir-
culating CD4+ T cells. These eﬀects were mostly retained two
months after therapy interruption. However, a trend, but not
a significant increase in CD4+ T-cell count was observed,
thus indicating that more studies are needed to check the
immunomodulating potentialities of HCQ. Some clinical
trials are currently in progress (ACTG A5258, http://clin-
icaltrials.gov/ct2/show/NCT00819390; CTN246, http://www
.hivnet.ubc.ca/clinical-studies/canadian-hiv-trials-database/
ctn-246/).
Strategies to restore the regenerative capacity of immune
system include the administration of recombinant inter-
leukin-2 (rIL-2) and IL-7. Endogenous IL-2 is produced
by activated CD4+ T cells and it is important for antigen
processing and induction of CD8+ T-cell cytotoxic activity;
in HIV-positive subjects, IL-2 levels are lower, so that
CD8+ cytotoxicity is impaired and the virus may easily
escape from the host immune system. Some clinical trials
demonstrated the eﬃcacy of one year-treatment with rIL-
2 plus HAART versus HAART alone in determining CD4+
T-cell gain [118, 119]; furthermore, the benefits of rIL-2
6 Clinical and Developmental Immunology
administration in terms of CD4+ count were maintained for
over 95 months in another follow up study [120]. First, rIL-
2 administration may help facing CD4+ T-cell loss, mainly
through the expansion of the naive CD4+ compartment;
it does not seem to be a mere matter of quantity but also
of quality: in fact, there was not only a numerical increase
but also a significant rise in functionally competent CD4+
CD28+ T cells, being CD28 a costimulatory molecule, whose
expression is needed for antigenic presentation [121, 122].
In addition, rIL-2 may promote the proliferation of CD8+
T cells [123] and inhibit HIV replication in macrophages
[124]. Despite the significant increase in CD4+ T-cell count,
the ESPRIT and SILCAAT study, two recent prospective,
randomized, controlled, phase III studies exploring the
clinical benefits of intermittent subcutaneous rIL-2 with
HAART versus HAART alone, have shown no significant
diﬀerences in HIV RNA levels and no clinical benefits to
the patients in the rIL-2 arm [125, 126]. As refers to IL-
7, a recent trial has demonstrated a sustained increase in T
cells after administration of recombinant human (rh) IL-7
to HIV-infected patients [127], because of both increase in
thymopoiesis as well as a direct increase in the magnitude of
antigen-driven peripheral T-cell expansion [128].
Another potential immunomodulatory strategy is asso-
ciated with NK-cell capability to exert a direct cytotoxic
eﬀect and to produce soluble factors able to control HIV
replication [129]. From this perspective, some authors have
evaluated the immunological eﬀects of IL-15, a pleiotropic
cytokine which is involved in NK-cell proliferation and
survival [130]. D’Ettorre et al. have recently reported that the
in vitro challenging of NK cells with IL-15 was able to sig-
nificantly reduce the level of viral p24 antigen in cocultured
infected CD4+ T cells and PBMCs media. Furthermore, IL-
15 stimulated NK cells reduced HIV DNA viral load both
in purified CD4+ T cells and PBMCs [131]. In a previous
study of the same group, IL-15 priming was shown to induce
a significant increase of IFN-gamma production in both
viremic and aviremic HIV-positive patients [132]. Tarkowski
et al. [133] found that the expression of IL-15, but not of
its receptor IL-15Rα, was significantly higher in the CD14+
monocytes of long-term nonprogressors than in those of
HIV-1 progressors or healthy controls; diﬀerences in IL-15
expression between patients with diﬀerent courses of HIV
infection may be indicative of a potential use of this cytokine
as a therapeutic agent.
Many strategies have been explored to eradicate residual
viremia in subjects on HAART: latently infected cells do
not diﬀer from uninfected cells, apart from the presence
of integrated HIV DNA but, when activated, these cells
may become vulnerable to immune-mediated killing and
to antiretrovirals, so that a current “hot topic” is focused
on reactivating latently infected cells, in order to induce
integrated HIV expression; for example, IL-7 has been shown
to induce productive infection from latently infected CD4+
T cells in vitro, through the activation of the Jak-Stat pathway
[127, 134, 135] and it is currently ongoing clinical trials,
to determine if it may be eﬀective to reduce in vivo latent
reservoirs (ERAMUNE, http://www.clinicaltrials.gov). It has
been recently shown that the stimulation of CD4+ T cells
from viremic donors with IL-7 or IL-15 was able to induce
in both cases viral production in productively infected cells,
even if these cytokines showed a diﬀerent impact on the
maintenance of latently infected CD4+ T cells: in fact, IL-
7 had a major eﬀect on homeostatic proliferation of cells
harboring integrated HIV DNA, whereas IL-15 promoted
the diﬀerentiation of Tcm CD4+ T cells and increased the
percentage of short-lived eﬀector memory (Tem) T cells
[136].
The upregulation of cellular transcription has been sug-
gested as another strategy to induce HIV genome expression
and reverse latency, for instance by promoting histone
acetylation [137]. Histone deacetylase inhibitors (HDACis),
such as valproic acid, sodium butyrate, and suberoylanilide
hydroxamic acid (SAHA), have been shown to enhance
cellular transcription, including HIV LTR [138]; however,
some retrospective studies failed to demonstrate a significant
reduction of latent reservoirs when administering valproic
acid [139–141]. Due to the fact that active nuclear factor-
kappa B (NF-κB) is a positive regulator of HIV expression,
the use of the NF-κB activator prostratin, in combination
with HDACis, has been shown to enhance HIV transcription
in vitro [142, 143]. Mehla et al. have recently reported the
in vitro capability of bryostatin, a Protein Kinase C (PKC)
agonist, to reactivate latent viral infection in monocytic and
lymphocytic cells, mainly because of PKC-induced activa-
tion of NF-κB [144]. In addition, considering that DNA
methylation prevents HIV expression, the use of methylation
inhibitors, such as decitabine, has been proposed to eliminate
HIV from latently infected resting CD4+ T cells [145,
146]. Anyhow, the in vitro eﬃcacy of these families of
compounds needs to be tested first in animal models and
then in well-designed and well-tolerated clinical trials, to
understand if the “reactivation strategy” may also work
in vivo.
Recently, it has been suggested that compounds able to
promote the diﬀerentiation of the long-lived Tcm and Ttm
CD4+ T cells, which play amain role in HIV persistence [89],
into Tem-like phenotypes, may contribute to the restriction
of the viral reservoir. The gold-based compound auranofin,
which acts through the induction of reactive oxygen species,
has been shown to accelerate CD4+ T-cell turnover, thus
inducing long-lived memory cells to progress to short-lived
phenotypes and die [147].
Finally, therapeutic vaccination has been evaluated over
the last years, with mixed results, as a strategy aiming at
boosting immunity to HIV, generating HIV-specific CD4+
and CD8+ T-cell responses, possibly able to control viral
replication and enhance immune recovery [148, 149].
6. Conclusions
HAART has profoundly changed the natural history of HIV
infection, but a good suppression of HIV does not mean viral
elimination. We are still looking for therapeutic approaches
able to eradicate the virus; the persistency of latently infected
cells and latent reservoirs represents indeed amajor challenge
for the virologists and clinicians, considering that residual
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LLV works as a trigger for immune activation and increased
T-cell apoptosis.
Furthermore, not all virologically suppressed patients
are able to eﬀectively recover their CD4+ T-cell count,
thus exposing immunologic nonresponders to a significant
risk of both AIDS-related and non-AIDS-related morbidi-
ties. Despite the ever-growing number of new available
antiretrovirals, giving us new “weapons” to control viremia,
the approach to patients with poor immune recovery
is challenging; immune modulation, together with drugs
targeting the latent reservoirs, appear the most encouraging
options. Further studies are needed to better understand
the mechanisms that influence immune restoration and to
validate in vivo the evidence coming from in vitro studies.
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